DZ Bank AG Reaffirms Neutral Rating for Evotec AG (EVTCY)
A number of other brokerages also recently issued reports on EVTCY. Zacks Investment Research downgraded shares of Evotec AG from a buy rating to a hold rating in a report on Wednesday, November 9th. Deutsche Bank AG reaffirmed a neutral rating on shares of Evotec AG in a research note on Friday, November 18th.
Shares of Evotec AG (NASDAQ:EVTCY) remained flat at $16.61 on Tuesday. The company had a trading volume of 1 shares. The stock has a market capitalization of $1.10 billion and a P/E ratio of 60.62. Evotec AG has a 12 month low of $6.56 and a 12 month high of $16.68. The company’s 50-day moving average is $14.05 and its 200 day moving average is $10.95.
TRADEMARK VIOLATION WARNING: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and republished in violation of United States and international copyright and trademark law. The correct version of this piece can be accessed at http://www.dailypolitical.com/2017/01/13/dz-bank-ag-reaffirms-neutral-rating-for-evotec-ag-evtcy.html.
About Evotec AG
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator’s targets and programs.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.